Brokerages Set Evolus, Inc. (NASDAQ:EOLS) Target Price at $21.25

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned an average recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $21.25.

Several research analysts recently weighed in on EOLS shares. BTIG Research reiterated a “buy” rating and set a $18.00 price target on shares of Evolus in a research report on Monday, September 8th. Needham & Company LLC reaffirmed a “hold” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, August 6th. Wall Street Zen upgraded shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. HC Wainwright lowered their price target on shares of Evolus from $27.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research report on Monday, November 17th.

Evolus Stock Down 1.6%

Shares of EOLS opened at $6.74 on Friday. The company has a market cap of $436.89 million, a price-to-earnings ratio of -7.33 and a beta of 0.97. Evolus has a twelve month low of $5.71 and a twelve month high of $17.12. The company has a 50 day moving average of $6.58 and a two-hundred day moving average of $7.99.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Evolus had a negative return on equity of 759.04% and a negative net margin of 20.49%.The company had revenue of $68.97 million during the quarter, compared to analysts’ expectations of $91.23 million. Evolus has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Evolus will post -0.61 EPS for the current year.

Institutional Investors Weigh In On Evolus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Manchester Capital Management LLC acquired a new position in Evolus in the second quarter valued at approximately $26,000. State of Alaska Department of Revenue purchased a new stake in Evolus in the third quarter valued at $26,000. Wexford Capital LP acquired a new position in shares of Evolus in the 3rd quarter valued at $37,000. AlphaQuest LLC acquired a new position in shares of Evolus in the 1st quarter valued at $39,000. Finally, State of Wyoming grew its holdings in shares of Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company’s stock worth $45,000 after purchasing an additional 3,409 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.